Update: FDA approves Inovio's Voceryq for a rare airway disease
The FDA granted accelerated approval to Inovio's DNA immunotherapy Voceryq on 30 October 2026; 7 of 26 patients needed no surgery in a year.
Update: the outcome we flagged as pending on 30 October is now known. The US Food and Drug Administration (FDA) granted accelerated approval to Inovio Pharmaceuticals' Voceryq, formerly INO-3107, on 30 October 2026. It treats adults with recurrent respiratory papillomatosis (RRP), a rare airway disease. The FDA calls it the first plasmid DNA-based immunotherapy it has approved. The approval is conditional on further proof of benefit.
What the FDA approved
Voceryq is two plasmids, small loops of DNA. One carries instructions for HPV proteins and the other for IL-12, a molecule that boosts immune response. It is injected into a muscle and delivered with the CELLECTRA 5PSP device, which uses brief electrical pulses (electroporation) to help cells take up the DNA. The FDA says approval rests on a fall in how often surgery is needed, an intermediate endpoint "reasonably likely" to predict real benefit. That is what "accelerated approval" means: early evidence now, confirmation later. The product has Breakthrough Therapy and Orphan Drug status. The FDA release does not state the dose schedule.
The trial evidence
RRP is caused by HPV types 6 and 11. Wart-like growths return in the airway, mostly near the voice box, and surgery removes them but not the virus, so patients often need repeat operations. The FDA says the study was open-label (everyone knew they were treated) and multicentre, with 32 adults who had at least two surgeries in the previous 12 months. Of 26 patients who had at least three baseline surgeries, 7 (27%) needed no surgery in the first year. Inovio's own labelling summary, reported by BiopharmaWatch, gives a 95% confidence interval of 12% to 48%, which shows how wide the uncertainty is in so small a group. There was no placebo group.
The small trial means the result carries a wide range. The chart shows the observed rate and the 95% confidence interval that Inovio's labelling summary gives.
Safety, cost of the conditions and the market
The most common side effects were injection-site reactions, headache, fatigue, high blood pressure, nausea and dizziness. Electroporation can cause brief muscle contractions, bleeding at the site, anxiety and fainting-type reactions. BiopharmaWatch, which draws on Inovio's announcement, says ordering and shipping should begin in about 60 days, with full rollout in the first quarter of 2027, that Inovio must submit a draft confirmatory protocol by the end of 2026, and that it estimates at least 25,000 prevalent US patients. The same page lists about $37 million in liquidity and a runway of about four months, a point the page itself flags as a dilution risk. These are company or aggregator figures, not FDA statements. Precigen's Papzimeos, approved in August 2025 for the same disease, is a competitor, as we noted on 30 October. We did not open a source for how its shares moved.
What it means for readers
For patients and families, this is a US approval; nothing indicates India has approved or imported it, and access here would need separate regulatory steps. Whether it works as well as hoped is the open question: 27% with no surgery is a modest result, and the FDA's own wording signals that confirmation is still needed. Treatment choices belong with a specialist; this is not medical advice. For the wider sector, the approval shows the FDA will accept a surgery-frequency endpoint in a rare disease, which matters to other small biotech firms.
The calculator below turns the trial's count into a rate and shows how little a small sample pins down. It is arithmetic on the trial's numbers, not a prediction for any patient.
What to watch next
Inovio has a conference call set for 2 November 2026. Watch for the confirmatory trial design the FDA agrees, the first shipments in about 60 days, the price, and the company's funding plans given its stated cash runway.
Key takeaways
- The FDA granted Voceryq accelerated approval on 30 October 2026, the first plasmid DNA-based immunotherapy approved in the US.
- In the study, 7 of 26 patients (27%) with at least three baseline surgeries needed none in the first year.
- Continued approval depends on confirmatory trials, and the study had no placebo group.
- The approval applies in the US only; nothing indicates availability in India.
Sources
- [FDA: FDA approves first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis](https://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis)
- [BiopharmaWatch: INOVIO (INO) FDA accelerated approval of VOCERYQ](https://www.biopharmawatch.com/news/INO/inovio-fda-accelerated-approval-voceryq-rrp)
Tags: FDA Drug approval Inovio Rare disease Biotech